Objectives: Granulosa cell tumors (GCTs) comprise 2-5% of ovarian tumors. Serum Müllerian Inhibiting Substance (MIS, also known as anti-Müllerian hormone, or AMH) levels have been validated as a marker of GCT recurrence and progression. There has been little correlation between serum MIS/AMH levels and several clinical parameters in GCTs, including tumor burden. We have performed a retrospective review correlating aggregate tumor mass as reported by pathologic examination or by radiology with serum MIS/AMH levels drawn on the date of examination. Methods: We retrospectively identified 32 GCT patients at our institution over the last 15 years who had serum MIS/AMH measurements. Patients who had serum MIS/AMH measurements within three days of surgery or on the same day as abdominal computerized tomography scan (CT) or magnetic resonance imaging (MRI) were further evaluated. Results: We found a significant direct correlation between patient serum MIS/AMH levels and gross aggregate tumor mass determined by pathology (slope = 15.4 ± 6.06, r = 0.65, p < 0.04) or by radiographic aggregate tumor mass for all data points identified (slope = 0.07 ± 0.03, r = 0.33, p < 0.04) and after correcting for selection bias (slope = 1.45 ± 0.17, r = 0.93, p < 0.01). We also identified a significant difference between serum MIS/AMH levels between samples drawn the same day as negative and positive abdominal CT or MRI scans (8.16 ± 1.54 vs. 158.7 ± 32.2 ng/ml, p < 0.0001). Conclusions: These data indicate a significant direct correlation between serum MIS/AMH levels and both gross and radiographic aggregate tumor mass in GCT patients. Together with the current literature, the present data argue for a more prominent role for serum MIS/AMH in the management of GCTs.
- Adult granulosa cell tumor
- Anti-Müllerian hormone
- Müllerian Inhibiting Substance
- Ovarian sex-cord stromal tumor
ASJC Scopus subject areas
- Obstetrics and Gynecology